Ask Warren

Aptabio Therapeutics

293780 · KOSDAQ · ₩293780 · 압타바이오

₩5,090▼ ₩220 (4.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩1.6B₩957M₩1B₩1.2B₩1.1B₩383M₩744M₩859M
Cost of sales₩626M₩504M₩716M₩622M₩671M₩359M₩652M₩783M
Gross profit₩977M₩454M₩285M₩570M₩452M₩23M₩92M₩76M
Operating income−₩3.6B−₩6.1B−₩5.7B−₩3.4B−₩4.1B−₩2.6B−₩6.6B−₩5.9B
Net income₩1.1B−₩6.4B−₩6.5B−₩3.1B−₩4.2B−₩2.6B−₩10B−₩8B
Net income to shareholders₩1.1B−₩6.4B−₩6.5B−₩3.1B−₩4.2B−₩2.6B−₩10B−₩8B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩54B₩54B₩60B₩67B₩70B₩72B₩77B₩83B
Current assets₩23B₩17B₩25B₩24B₩27B₩29B₩35B₩43B
Cash and equivalents₩15B₩7.8B₩16B₩19B₩22B₩19B₩26B₩32B
Total liabilities₩12B₩13B₩13B₩23B₩22B₩20B₩23B₩34B
Current liabilities₩8.9B₩9.6B₩9.7B₩19B₩18B₩16B₩20B₩17B
Borrowings₩7.2B₩7.2B₩7.2B₩16B₩16B₩16B₩16B₩32B
Total equity₩42B₩41B₩47B₩45B₩48B₩52B₩54B₩49B
Shareholders' equity₩42B₩41B₩47B₩45B₩48B₩52B₩54B₩49B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩2.6B−₩8B−₩4B−₩2.7B−₩2B−₩6.5B−₩4.1B−₩2B
Free cash flow−₩2.6B−₩8B−₩4B−₩2.7B−₩2B−₩6.5B−₩4.1B−₩2B

Consolidated where available. Amounts in won.

Also known as: Aptabio Therapeutics / 압타바이오 / 293780 / KRX:293780

Source: KRX statistical information